SLNO
The lawsuit has a deadline now
Faruqi & Faruqi says investors in Soleno Therapeutics have until May 5, 2026 to seek lead-plaintiff status in a federal securities class action. In plain English: the legal process is moving, and the company’s stock could stay under a microscope while the case works its way through the system.
Why investors should care
The complaint centers on claims that Soleno and its executives allegedly downplayed safety issues tied to DCCR, its Phase 3 program for hyperphagia in Prader-Willi syndrome. The headline risk here isn’t just courtroom drama — it’s the possibility that the market keeps pricing in more uncertainty around the drug’s launch, adoption, and regulatory path.
Why this still matters for the stock
The article points to a chain reaction that already hit shares hard in 2025: a critical Scorpion Capital report, a Form 8-K about a patient death, and a rough Q3 update that said the controversy disrupted the launch trajectory. In other words, this isn’t a fresh surprise so much as another reminder that the legal and reputational baggage is still very much attached to the story.
Big picture
For investors, the key question is whether the lawsuit becomes a short-term overhang or a longer-term value crater. Either way, the case keeps the market focused on the same thing it’s been worrying about for months: can Soleno prove DCCR is commercially viable without the safety narrative stealing the whole show?